Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in severe atopic dermatitis (LIBERTY AD CAFÉ)
NCT02755649Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percentage of Participants With Eczema Area and Severity Index 75 at 16 weeks. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02755649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755649.